LOGIN  |  REGISTER
Chimerix

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

May 29, 2025 | Last Trade: US$20.12 1.59 8.58

SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences in June.

Jefferies Global Healthcare Conference

Format: Fireside chat and 1x1 meetings
Date/time: Thursday, June 5 at 8:10 a.m. ET
Location: New York, NY

Goldman Sachs Global Healthcare Conference

Format: Fireside chat and 1x1 meetings
Date/time: Wednesday, June 11 at 10:40 a.m. ET
Location: Miami, FL

The live and archived webcasts of the fireside chats will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and a replay will be available for 90 days.

About Structure Therapeutics 

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.

Investors:
Danielle Keatley
Structure Therapeutics Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
Dan Budwick
1AB
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page